Eikon Therapeutics, Inc. (EIKN) stock
EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$5.15−0.23 (-4.36%)
Close on Nov 17, 2026Market cap $278.95MP/E –Yield –
Eikon Therapeutics cash
Cash and short-term investments held at the end of each period.
Eikon Therapeutics's cash was $531.18M at Jun 30, 2026. For fiscal 2025 it was $335.98M.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $335.98M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $531.18M | +159.6% |
| Q1 FY2026 | Mar 31, 2026 | $512.18M | – |
| Q4 FY2025 | Dec 31, 2025 | $335.98M | – |
| Q2 FY2025 | Jun 30, 2025 | $136.56M | – |
| Q1 FY2025 | Mar 31, 2025 | $204.58M | – |
See a number that looks wrong?